FINNENCE ▪ THE WIRE FILE
THE WIRE · № 84746
SEC Filing■ Unclear/unknown
PEP filed 4 on 2026-10-16
KINDSEC Filing
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A Form 4 discloses insider transactions; without share counts or buy/sell direction, no signal can be inferred.
Routine insider filing with no disclosed transaction details
CATALYST TO WATCH
Full Form 4 disclosure of shares and price
MAIN RISK
Details may reveal insider selling pressure
FULL DISPATCH
PEP (CIK 0001061272) filed a 4 on 2026-10-16.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTPepsiCo · PEP
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects — Onconic Therapeutics Inc.2026-10-15 12:00 UTC
New Phase 3 trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects — Onconic Therapeutics Inc.2026-10-15 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer — Hinova Pharmaceuticals Inc.2026-10-15 12:00 UTC
New Phase 3 trial: A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer — Hinova Pharmaceuticals Inc.2026-10-15 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants — Regeneron Pharmaceuticals2026-10-15 12:00 UTC
New Phase 3 trial: A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants — Regeneron Pharmaceuticals2026-10-15 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity — Pfizer2026-10-15 12:00 UTC
New Phase 3 trial: A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity — Pfizer2026-10-15 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With Hemophilia — Shanghai RAAS Blood Products Co., Ltd.2026-10-15 12:00 UTC
New Phase 3 trial: A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With Hemophilia — Shanghai RAAS Blood Products Co., Ltd.2026-10-15 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.